Mediwound Ltd (MDWD)

[midastouch017]

Analysts Anticipate MediWound Ltd. (NASDAQ:MDWD) Will Announce Quarterly Sales of $5.59 Million

https://www.marketbeat.com/instant-alerts/nasdaq-mdwd-consensus-analyst-rating-2021-01/

WEDNESDAY, JANUARY 6, 2021 | MARKETBEAT
MediWound logoWall Street analysts expect MediWound Ltd. (NASDAQ:MDWD) to announce sales of $5.59 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for MediWound's earnings. The lowest sales estimate is $5.47 million and the highest is $5.70 million. MediWound posted sales of $5.44 million in the same quarter last year, which suggests a positive year-over-year growth rate of 2.8%. The business is scheduled to issue its next earnings results on Tuesday, February 23rd.

On average, analysts expect that MediWound will report full-year sales of $20.68 million for the current year, with estimates ranging from $20.56 million to $20.80 million. For the next year, analysts anticipate that the company will post sales of $31.27 million, with estimates ranging from $27.03 million to $35.50 million. Zacks Investment Research's sales averages are an average based on a survey of analysts that that provide coverage for MediWound.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). MediWound had a negative net margin of 53.12% and a negative return on equity of 94.63%. The company had revenue of $6.63 million for the quarter, compared to analyst estimates of $6.49 million.

A number of research analysts recently weighed in on MDWD shares. TheStreet lowered shares of MediWound from a "c-" rating to an "e+" rating in a research note on Tuesday, September 8th. BTIG Research started coverage on shares of MediWound in a report on Wednesday, September 23rd. They set a "buy" rating and a $6.00 price target for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. MediWound currently has an average rating of "Buy" and a consensus target price of $5.38.


A number of large investors have recently made changes to their positions in the stock. ExodusPoint Capital Management LP acquired a new position in MediWound in the third quarter valued at $38,000. Thomasville National Bank increased its stake in shares of MediWound by 36.8% during the fourth quarter. Thomasville National Bank now owns 52,000 shares of the biopharmaceutical company's stock worth $192,000 after acquiring an additional 14,000 shares during the period. Marshall Wace LLP acquired a new position in shares of MediWound during the first quarter worth about $93,000. Squarepoint Ops LLC acquired a new position in shares of MediWound during the third quarter worth about $116,000. Finally, Acadian Asset Management LLC increased its stake in shares of MediWound by 36.2% during the third quarter. Acadian Asset Management LLC now owns 259,150 shares of the biopharmaceutical company's stock worth $975,000 after acquiring an additional 68,918 shares during the period. Hedge funds and other institutional investors own 15.46% of the company's stock.

MDWD stock opened at $3.99 on Wednesday. The company's 50-day simple moving average is $3.78 and its 200-day simple moving average is $3.60. MediWound has a 52-week low of $1.44 and a 52-week high of $4.44. The firm has a market cap of $108.57 million, a P/E ratio of -9.97 and a beta of 1.67.